Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2005;111:1747-1755
Published online before print April 4, 2005, doi: 10.1161/01.CIR.0000160866.90148.76
Free Article
This Article
Free upon publication Free Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
111/14/1747    most recent
01.CIR.0000160866.90148.76v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stone, P. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stone, P. H.
Related Collections
Right arrow Exercise testing
Right arrow Exercise/exercise testing/rehabilitation
Right arrow Chronic ischemic heart disease
Right arrow Coronary circulation
Right arrow Lipid and lipoprotein metabolism

(Circulation. 2005;111:1747-1755.)
© 2005 American Heart Association, Inc.


Coronary Heart Disease

Effect of Intensive Lipid Lowering, With or Without Antioxidant Vitamins, Compared With Moderate Lipid Lowering on Myocardial Ischemia in Patients With Stable Coronary Artery Disease

The Vascular Basis for the Treatment of Myocardial Ischemia Study

Peter H. Stone, MD; Donald M. Lloyd-Jones, MD, SM; Scott Kinlay, MD, PhD; Balz Frei, PhD; William Carlson, MD, PhD; Joel Rubenstein, MD; Thomas C. Andrews, MD; Michael Johnstone, MD; George Sopko, MD; Holly Cole, BS; John Orav, PhD; Andrew P. Selwyn, MD; Mark A. Creager, MD, for the Vascular Basis Study Group

From Brigham & Women’s Hospital (P.H.S., S.K., W.C., H.C., J.O., A.P.S., M.A.C.); Massachusetts General Hospital, Boston, Mass (D.M.L.-J.); Beth Israel Deaconess Medical Center, Boston, Mass (M.J.); Newton Wellesley Hospital (J.R.), Newton, Mass; University of Texas Southwestern Medical Center, Dallas (T.C.A.); Oregon State University, Corvallis (B.F.); and National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Md (G.S.).

Correspondence to Peter H. Stone, MD, Cardiovascular Division, Brigham & Women’s Hospital, 75 Francis St, Boston, MA 02115. E-mail pstone{at}partners.org

Received July 21, 2004; revision received December 20, 2004; accepted December 29, 2004.

Background— Lipid lowering with statins prevents adverse cardiac events. Both lipid-lowering and antioxidant therapies may favorably affect vasomotor function and thereby improve ischemia.

Methods and Results— In a randomized, double-blind, placebo-controlled trial, 300 patients with stable coronary disease, a positive exercise treadmill test, 48-hour ambulatory ECG with ≥1 episode of ischemia, and fasting total cholesterol of 180 to 250 mg/dL were assigned to 1-year treatment with intensive atorvastatin to reduce LDL to <80 mg/dL (n=96), intensive atorvastatin to reduce LDL to <80 mg/dL plus antioxidant vitamins C (1000 mg/d) and E (800 mg/d) (n=101), or diet and low-dose lovastatin, if needed, to reduce LDL to <130 mg/dL (n=103; control group). Ischemia end points, including ambulatory ECG monitoring and exercise treadmill testing, and endothelial assessment using brachial artery flow-mediated dilation were obtained at baseline and at 6 and 12 months. Baseline characteristics were similar in all groups. LDL decreased from {approx}153 mg/dL at baseline in the 2 atorvastatin groups to {approx}83 mg/dL at 12 months (each P<0.0001) and from 147 to 120 mg/dL in the control group (P<0.0001). During ambulatory ECG monitoring, mean number of ischemic episodes per 48 hours decreased 31% to 61% in each group (each P<0.001; P=0.15 across groups), without a change in daily heart rate activity. Mean duration of ischemia for 48 hours decreased 26% to 62% in each group (each P<0.001; P=0.06 across groups). Mean exercise duration to 1-mm ST-segment depression significantly increased in each group, but total exercise duration and mean sum of maximum ST depression were unchanged. Angina frequency decreased in each group. There was no incremental effect of supplemental vitamins C and E on any ischemia outcome. Flow-mediated dilation studies indicated no meaningful changes.

Conclusions— Intensive lipid lowering with atorvastatin to an LDL level of 80 mg/dL, with or without antioxidant vitamins, does not provide any further benefits in ambulatory ischemia, exercise time to onset of ischemia, and angina frequency than moderate lipid lowering with diet and low-dose lovastatin to an LDL level of <120 mg/dL.


Key Words: antioxidants • cholesterol • coronary disease • exercise • vasoconstriction




This article has been cited by other articles:


Home page
CMAJHome page
K. Josan MD, S. R. Majumdar MD MPH, and F. A. McAlister MD MSc
The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials
Can. Med. Assoc. J., February 26, 2008; 178(5): 576 - 584.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
J. Afilalo, A. A Majdan, and M. J Eisenberg
Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials
Heart, August 1, 2007; 93(8): 914 - 921.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
P. Deedwania, P. H. Stone, C. N. Bairey Merz, J. Cosin-Aguilar, N. Koylan, D. Luo, P. Ouyang, R. Piotrowicz, K. Schenck-Gustafsson, P. Sellier, et al.
Effects of Intensive Versus Moderate Lipid-Lowering Therapy on Myocardial Ischemia in Older Patients With Coronary Heart Disease: Results of the Study Assessing Goals in the Elderly (SAGE)
Circulation, February 13, 2007; 115(6): 700 - 707.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
D. M. Musher
Undisclosed Conflicts of Interest
Ann Intern Med, February 7, 2006; 144(3): 225 - 225.
[Full Text] [PDF]


Home page
ANN INTERN MEDHome page
P. H. Stone
Undisclosed Conflicts of Interest
Ann Intern Med, February 7, 2006; 144(3): 225 - 226.
[Full Text] [PDF]


Home page
QJMHome page
H.T. Ong
The statin studies: from targeting hypercholesterolaemia to targeting the high-risk patient
QJM, August 1, 2005; 98(8): 599 - 614.
[Abstract] [Full Text] [PDF]